Empatica
Empatica makes medical grade wearables and the algorithms and software behind them, for clinical research, epilepsy and Parkinson's disease. Matteo Lai and MIT's Rosalind Picard founded it in Milan in 2011 with two others, and it now runs from Cambridge, Massachusetts, and Milan, with 12 FDA clearances, more than 100,000 devices deployed and availability in over 160 countries.
The Empatica Health Monitoring Platform pairs the EmbracePlus or EmbraceMini wearable with study apps, an eCOA tool and a Cloud API, and offers more than 300 digital measures of sleep, activity, movement and physiology. Empatica says more than half of the top 20 pharmaceutical companies use it in trials.
EpiMonitor, for people with epilepsy aged 6 and older, runs the learned EpiAlgo seizure detector on an EmbracePlus watch and calls and texts chosen caregivers when it spots a possible generalized tonic clonic seizure; wearers can cancel false alarms and keep a seizure diary. It costs $399 for the device plus a subscription from $17.40 a month. After buying PKG Health in October 2025, Empatica won FDA clearance for Parkinson's monitoring in August 2026, tracking bradykinesia, dyskinesia, tremor, gait and medication timing, and launched WellPD for patients at home in October 2026. Research and clinic programs are priced with the sales team.
Capability Axes
An AI Health Index grade measures what a buyer can verify from public sources on the date shown. It is not a rating of how good the product is. A vendor can build an excellent system and grade low on an axis because it publishes nothing an outsider can check. How grades read
Learned analysis sits inside a larger hardware and research business. EpiMonitor's machine learning algorithm reads the wearable's signals for patterns of generalized tonic clonic seizures and alerts caregivers, and the research platform turns continuous sensor streams into more than 300 digital measures for trials, from sleep and activity to movement disorder scores. The PKG algorithms Empatica acquired in 2025 do the same for Parkinson's symptoms.
Wearable manufacturing, raw data export and study administration keep their value without any model, and the portfolio mixes Empatica's own algorithms with partners'.
A suspected seizure starts a countdown that lets the wearer cancel a false alarm before caregivers get calls and texts. Detection sensitivity can be raised, lowered or switched off, and a manual alert is always available. Alerts need a paired phone, Bluetooth, internet access and the phone within 15 feet.
EpiMonitor contacts the caregivers the wearer chose rather than emergency services, and it neither predicts seizures nor replaces ongoing supervision. High and lower sensitivity modes trade missed seizures against false alarms, and no escalation path is set out for when caregivers do not answer.
The current EpiMonitor clearance names EpiAlgo 2.1 as the detection algorithm running on the watch, fed by electrodermal activity and accelerometer signals, with further processing for the diary, sleep and activity features. The algorithm line was trained with machine learning on hospital epilepsy monitoring data, and the 2025 change kept that algorithm while moving it from Embrace2 to EmbracePlus hardware.
Model architecture, the full makeup of the training data and the update history for every research measure are not given. Seizure forecasting is still an investigational project, separate from the marketed detection.
The seizure detection chain starts with Empatica's own wearable and EpiAlgo software, then passes an event through the paired phone and cloud services to phone and text delivery. Research data runs on Amazon Web Services. The research portfolio also uses partner algorithms, with McRoberts among the named collaborators, and the PKG movement algorithms came in through the 2025 acquisition.
No full map ties each digital measure to its developer, version, host and downstream processor, and clinical trial API access and caregiver alerts take different routes through the system.
EpiMonitor's clinical support rests on retrospective seizure detection analyses plus bench testing that bridges the older Embrace2 sensor setup to EmbracePlus; the 2025 submission included no new clinical study of the changed device. In a lower sensitivity hospital analysis, it caught 17 of 19 pediatric seizures and all 17 adult seizures. A separate real world dataset recorded detection of 1,011 of 1,157 pediatric events and 2,896 of 3,625 adult events.
The PKG Parkinson's algorithms appear in more than 70 peer reviewed publications. These results cover particular datasets and modes, not every measure in the research portfolio.
Research participants contribute deidentified physiological data and device details, while the study sponsor keeps the link to their identity, and research platform data can stay for 10 years after the provider agreement ends. The US EpiMonitor privacy policy separately allows service improvement, research, internal training and use of aggregated or deidentified information, and separates browsing and advertising data from the monitoring service.
No product wide ban on model training or common deletion deadline applies, because a research account and a direct epilepsy subscription follow different rules. Wearers can cancel false alarms, but no process for investigating harmful algorithm errors is described.
The research platform works with deidentified participant data, while the study provider controls identity and source records. Empatica says it cannot link study data back to a person and processes it to fulfill the provider agreement, and a separate data processing agreement makes customer instructions the basis for that processing. US EpiMonitor accounts follow their own consumer privacy terms.
No standard business associate agreement covering every product, subscription level and downstream processor is offered, and cloud infrastructure that can support HIPAA does not settle the contractual role in a given research or clinical deployment.
Empatica Srl holds ISO/IEC 27001:2022 certificate 01 153 2117571, issued by TÜV Rheinland and valid through October 30, 2028. Its scope covers managing wearable medical device manufacturing and designing and building software and platforms for physiological monitoring, and the September 2026 certificate and annex list Milan and Surrey sites and a June 2026 revision of the statement of applicability.
Empatica also holds ISO 13485 certification for medical device quality, a separate standard. The certificate is the company's own rather than its cloud host's, though it does not list every product version, subcontractor or customer setup.
EpiMonitor holds FDA 510(k) clearance K250515, granted June 19, 2025, for prescription seizure monitoring in people aged 6 and older, as an adjunct that detects possible generalized tonic clonic seizures through the wearable, app and caregiver alerts. Parkinson's monitoring was cleared under K260374 in August 2026 and carries CE MDR certification in Europe, and other clearances cover research platform configurations including EmbraceMini, for 12 in all.
A 2023 Class II recall remains open for Embrace2 lots G11 and H11 over shortened battery life, a lot specific correction separate from the EpiMonitor clearance, with replacement support.
Seizure detection results are reported separately for children and adults, including detection and false alarm rates. In the lower sensitivity hospital analysis, false alarms ran at 0.70 a day in the pediatric group and 0.28 a day in adults, and the real world analysis also reports the age groups apart, so the tradeoff is visible rather than assumed to be the same.
Those comparisons cover the seizure algorithm on its defined datasets. They do not show parity by skin tone, language or other neurological conditions, and the broader biomarker portfolio runs on different algorithms whose evaluation cannot be read off the epilepsy results.
Wearers can cancel a suspected false alarm and add or review seizure events in the diary. Detection results come with measured missed event and false alarm rates tied to datasets and observation time, so the performance claim can be tested.
The Embrace2 battery recall gives a separate hardware remedy: affected customers contacted about battery life can get a free replacement. That remedy is not an indemnity for a missed seizure or a slow caregiver response, research data questions generally go through the study provider, and no compensation commitment covers harm from an algorithm's output.
The Cloud API connects wearable data and participant management to a sponsor's or research organization's existing trial software, and raw and processed data can move in formats such as Avro and CSV into cloud storage for analysis. The Care App sends sensor data through the phone's internet connection.
EpiMonitor users can export a PDF diary to discuss with their clinician, and the Parkinson's offering gives clinicians a portal with PKG reports. None of these is a named production EHR connection with clinical read and write behavior; trial integration, a shared report and a clinician portal all sit outside the chart.
Seizure detection runs on the wearable itself, while alerts depend on a nearby phone, internet service and cloud communications. The research platform stores and processes participant data on cloud infrastructure in Virginia, with Amazon Web Services behind it, and organizations work through hosted research software and APIs.
The US EpiMonitor privacy terms allow transfers involving global affiliates and service providers, so the research platform's location does not set the rule for every consumer account. Tenant isolation and customer managed hosting are not described.
US EpiMonitor buyers pay $399 for the device plus a subscription. Under the schedule effective April 20, 2026, Basic is $17.40 a month or $191.40 a year, Standard $26.90 or $295.90, and Plus $52.90 or $581.90, replacing the older $15.90 starting price that still appears in an FAQ. A valid prescription is needed before a US order ships, and insurers decide reimbursement separately.
Research platform and organizational deals go through the sales team, and their implementation charges, minimum commitments and per study or per participant prices are not listed.
The epilepsy system serves adults and children aged 6 and older at home and in healthcare settings, focused on generalized tonic clonic events; it does not detect every seizure type or predict seizures. Trial teams collect physiological measures across sleep, activity and other research uses, and Empatica says more than half of the top 20 pharmaceutical companies use the platform.
PKG monitoring and WellPD extend it into Parkinson's care, and the PKG algorithms are used at more than 150 hospitals and clinical sites. WellPD launched in the US, UK, EU, Australia and Canada. Research measures in other therapeutic areas carry their own validation and regulatory limits.
Alternatives to Empatica
Other products that do the same kind of work as Empatica, and what each one does.
Vivalink sells the sensing and data layer that other organizations build monitoring products on.
Sibel Health makes soft, flexible, wireless sensors that stick to skin and monitor vital signs without cables.
Current Health gives health systems, community oncology practices and drug makers the monitoring and nursing infrastructure to deliver CAR T cell therapy, bispecific antibodies and other complex treatments outside the hospital, and to run hospital at home programs.
Biofourmis monitors patients at home and tries to detect deterioration before it becomes an admission.
iRhythm runs Zio, a long term ambulatory cardiac monitoring service.
Respiratory diagnostics company developing Sylvee, a chest worn wearable that projects low frequency sound into the lungs and analyzes the returning resonance with machine learning to measure lung volumes, trapped air, respiratory rate and breathing sounds, positioned for early COPD…
Pricing
Vendor-published figures are labeled as such. Figures labeled “Estimated” are derived from third-party sources and have not been confirmed by the vendor.
| Entry Price | Pricing Basis | BAA Tier | Implementation | Source |
|---|---|---|---|---|
|
$399 device plus subscription from $17.40 a month
$17.4 baseline
|
US EpiMonitor subscriptions effective April 20, 2026: Basic $17.40 monthly or $191.40 annually; Standard $26.90 monthly or $295.90 annually; Plus $52.90 monthly or $581.90 annually. The EmbracePlus device costs $399 separately. Research platform and organizational pricing is arranged with the sales team. | No standard business associate agreement covering every product and subscription level is offered. Research platform and consumer data arrangements have different scopes. | The consumer device charge is separate from the subscription. Research implementation, integration and study setup charges are not listed. | Vendor Published |
A US prescription is required before the EpiMonitor order ships. The April 2026 schedule replaces the older $15.90 starting subscription in an FAQ. Currency, availability and reimbursement vary by market and insurer. These consumer prices do not set a rate for clinical trials, the research platform or Parkinson's monitoring.